The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

COVID-19 'war games': the computer program that could help save your job

Wed, 11th Nov 2020 12:23

* Tech firm creates game to simulate impact of COVID layoffs

* 'Broad-front' cost-cutting strategy seen as more effective

* World of work on brink of revolution, creator says

By Sinead Cruise

LONDON, Nov 11 (Reuters) - Bank of England Chief Economist
Andy Haldane has signed up to judge the winner of a 'war game'
designed to help firms find alternatives to mass layoffs in the
face of a coronavirus-driven slowdown.

Confronted with the most unpredictable pandemic in memory,
cost-conscious firms have already axed millions of staff
worldwide, while UK redundancies hit a record high of 314,000 in
the quarter to Sept. 30, official data showed on Tuesday.

Unilever-owned tech firm uFlexReward created the
COVID-19 War Game to allow executives to explore the impact of
huge job cuts on their future earnings prospects.

"Many companies across the UK are facing financial strains
as a result of the COVID crisis," Haldane told Reuters.

"Simulation tools can help us understand how best to
alleviate these strains while preserving jobs, in a way that
helps both businesses when making difficult commercial decisions
and policymakers when making difficult economic decisions."

The game, designed during Britain's first lockdown this year
and available free to play on the uFlexReward website, calls on
players to devise a strategy to cut people costs of a fictional
firm by 20%.

Participants weigh up the pros and cons of large-scale
redundancies versus alternatives, for the long-term benefit of
the firm as well as the broader economy.

It collates staff salaries, pensions, bonuses and share
awards into one real-time cost-base, helping players see
different ways of trimming overheads more clearly.

This can include making lots of smaller cost cuts in a
so-called 'broad-front' approach, rather than one large saving
in more focused cuts like scrapping entire business units or the
staff bonus pool.

Financial firms have historically slashed highly paid
workforces on the eve of recession, only to rehire rapidly when
the economy rebounds.

Swapping this convention for a broad-front approach could
minimise the risks that employers end up understaffed and
under-skilled when the recovery kicks off, uFlexReward Chief
Executive Ken Charman said.

'CHANGE IS COMING'

Employers in multiple sectors are facing the prospect of a
broader revolution in the world of work, triggered by technology
and mass remote working.

"We are still stuck in a very Victorian view of what work is
- with fixed working days, for a single employer and in a
typically narrow role," Charman said.

"But change is coming that will allow people to be several
things at once ... if companies lose people who are highly
trained, experienced and loyal, they won't get them back," he
said.

Charman hopes the game might persuade employers to waive or
cut dividends as well as executive pay increases, and offer
job-sharing, reduced hours or part-time roles with flexibility
to work elsewhere to staff who might otherwise end up
unemployed.

Pushing through alternatives to mass layoffs will require
strong leadership and communication, particularly when thousands
of employee contracts need to be renegotiated, but retaining
staff could leave firms better placed when the recovery begins,
Charman said.

"Executives need to be willing to abandon the old
conventions; there will be resistance and they've got to be able
to convince people this is in their best interests," he said.

"Employers, big companies and big financial institutions are
part of our critical national infrastructure as much as the
National Grid. They are the engines of our growth, but they are
under threat."

Judging of the head-to-head version of the game, featuring
teams made up of executives from Unilever and NYSE-listed
technology services provider Endava, will take place on
Dec. 3.

Together with Haldane, AstraZeneca senior vice
president of reward and inclusion Rebekah Martin, Unilever head
of global reward Constantina Tribou, and author David Goodhart
are among those judging the strategies.
($1 = 0.7706 pounds)
(Reporting by Sinead Cruise; Editing by Jan Harvey)

More News
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more
26 Feb 2024 07:22

AstraZeneca's blood-disorder drug recommended for EU approval

(Sharecast News) - European regulators has given the green light to AstraZeneca's blood-disorder drug Voydeya, the biopharma giant announced on Monday.

Read more
22 Feb 2024 17:36

EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:

Read more
20 Feb 2024 10:29

AstraZeneca acquires US-based biopharmaceutical company

(Sharecast News) - Drugmaker AstraZeneca revealed late on Monday afternoon that it had successfully completed its acquisition of US-based biopharmaceutical company Icosavax.

Read more
20 Feb 2024 09:40

LONDON BROKER RATINGS: JPMorgan cuts Airtel Africa price target by 28%

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
19 Feb 2024 16:51

LONDON MARKET CLOSE: Europe lacks direction on quiet Monday

(Alliance News) - European markets lacked direction on Monday, after a quiet day as the US markets celebrated George Washington's birthday.

Read more
19 Feb 2024 15:59

London close: Stocks manage gains on globally quiet day

(Sharecast News) - London's financial markets finished in positive territory on Monday, with stocks closing in the green after overcoming minor losses earlier in the session.

Read more
19 Feb 2024 15:39

UPDATE: AstraZeneca completes USD1.1 billion acquisition of Icosavax

(Alliance News) - AstraZeneca PLC on Monday said it has completed the acquisition of Icosavax Inc.

Read more
19 Feb 2024 11:51

LONDON MARKET MIDDAY: Stocks lack direction amid quiet start to week

(Alliance News) - Stock prices in London lacked direction at midday Monday, amid a quiet start to the week.

Read more
19 Feb 2024 08:44

LONDON MARKET OPEN: Stocks drift; Currys surges on takeover interest

(Alliance News) - Stock prices in London were looking for direction early Monday, as investors weighed possible trajectories for US interest rate cuts and a China's economic recovery.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.